Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

TKT May Have Enablement Argument Vs. Amgen's EPO Patents, Judge Says

  • News

Executive Summary

Transkaryotic Therapies may have an enablement argument against Amgen's patents for erythropoietin, Judge William Young said during a hearing held March 27-28 in Boston federal court to define claims included in the EPO marketer's patents.

You may also be interested in...



TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins

Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.

TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins

Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.

Amgen/TKT EPO

Trial set for May 15 in EPO patent dispute. Amgen claims TKT's gene-activated erythropoietin infringes its Epogen patents (1"The Pink Sheet" April 3, p. 7). Judge William Young will hear the case in Boston federal court

Table

View full table

Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS035832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By